Parasitic Infections in HIV-Infected Patients

  • Authors: José M. Miró, MD, PhD; Miriam J. Álvarez-Martínez, MD, PhD (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/20/21 (What's New)

Summary

  • Guidelines on opportunistic infections indicate that benznidazole and nifurtimox are useful for reducing parasitemia and preventing clinical manifestations in congenital, acute phases and reactivations of Chagas disease (Table 11) (Management Guidelines)[CDC OI] (Management Guidelines)[GESIDA OI]
  • Benznidazole is approved by the FDA for children 2-12 years of age but is commercially available for patients with Chagas disease without limitation of age. Nifurtimox is approved by the FDA for children from birth to 18 years of age
  • Optimal duration of therapy has not been established in patients with HIV

Action required